Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

Inclusion Criteria

• •Treatment history of ATTR-CM is one of the following:
• •Naive participants: newly diagnosed with ATTR-CM and no prior treatment with drugs for ATTR-CM
• •Switch participants: Participants who are using tafamidis, a TTR stabilizer, as treatment for ATTR-CM and who, in the judgment of the post-marketing clinical trial investigator (co-principal investigator), can be expected to benefit from switching to acoramidis.
• •Naive participants must meet the following requirements:
• •1. History of hospitalization for heart failure or heart failure symptoms requiring treatment, including diuretics
• •2. Echocardiographic end-diastolic ventricular septal thickness greater than 12 millimeters (mm)
• •3. Confirmed diagnosis of ATTR-CM (wild type or mutant) by one of the following diagnostic methods
• •1. Tissue biopsy shows amyloid deposition and TTR precursor protein is identified by immunohistochemistry or mass spectrometry.
• •2. Bone scintigraphy showing strong accumulation \*\* (Perugini score ≥ 2) consistent with myocardium and no M protein, negating the possibility of AL amyloidosis